Granic I, Dolga AM, Nijholt IM, Van Dijk G, Eisel ULM
Disclosures: Marti Ortega-Ribera: Nothing to Disclose, Radhika Joshi: Nothing to Disclose, Sergi Guix-Muntet: Nothing to Disclose, Veronika Brezani: Nothing to Disclose, Prashanth Thevkar Nagesh: Nothing to Disclose, Viliam Brezani: Nothing to Disclose, Arman Patel: Nothing to Disclose, Mrigya Babuta: Nothing to Disclose, Yuan Zhuang: Nothing to Disclose, Jordi Gracia-Sancho: Gilead Sciences: Independent Contractor, Novo Nordisk: Independent Contractor, Inventiva: Independent Contractor, Barcelona Liver Bioservices: Stock privately held company, Oncomatryx: Independent Contractor, Quinton: Independent Contractor, Gyongyi Szabo: CYTA Therapeutics: Consultant, Durect Corporation: Consultant, Merck: Consultant, Pandion Therapeutics: Consultant, Pfizer: Consultant, Terra Firma: Consultant, LabCorp: Consultant, Takeda: Consultant, Surrozen: Advisor, Intercept: Advisor, Evive: Advisor, Glympse Bio, Inc (acquired by Sunbird Bio): Advisor, Satellite Biosciences: Advisor, Zomagen Bioscience/Ventyx Biosciences: Consultant, Springer Nature Group: Royalties or patent beneficiary, UpToDate Inc: Royalties or patent beneficiary 983 SAFETY, TOLERABILITY, AND OUTCOMES OF SOFOSBUVIR/VELPATASVIR IN TREATMENT OF CHRONIC HEPATITIS C VIRUS DURING PREGNANCY: INTERIM RESULTS FROM THE STORC STUDY Catherine Chappell 1 Jasmin Charles 2 Marcela Smid 2 Kara Rood 3 John Cafardi 4 Tatyana Kushner 5 Mia Biondi 6 Jordan Feld 7 Mark Yudin 8 Genevieve Eastabrook 9 Sarah Osmundson 10 Todd Davies 11 Meyn Leslie 1 Cathleen Letterio 12 Kyung min Kwon 12 Bruce Kreter 13 Sharon Hillier 1 , 1 University of Pittsburgh, 2 University of Utah, 3 Ohio State University, 4 The Christ Hospital, 5 Mount Sinai Medical Center, 6 University Health Network, 7 Toronto General Hospital, 8 Unity Health Toronto, 9 London Health Sciences Centre, 10 Vanderbilt University, 11 Marshall University, 12 Gilead Sciences, 13 Gilead Sciences, Inc
Data were analyzed using Biacore Insight software, and binding kinetics were fitted using a 1:1 Langmuir interaction model
Het is dagelijks te gebruiken door volwassenen en kinderen vanaf 4 jaar.De aanbevolen dosering is 1 capsule per dag
M., Zahler, C
Kuang, F., Liu, J., Tang, D
